Medical Disclaimer

Full Disclaimer

InsulinMe is a personal insulin dose tracker. It is NOT a medical device, has NOT been evaluated or approved by any regulatory agencies, and does NOT provide medical advice, diagnosis, or treatment recommendations.

The Insulin on Board (IOB) calculation uses insulin activity models based on published clinical data for informational purposes only. All calculations are estimates and may differ significantly from actual insulin activity in your body. The app does not account for individual metabolism, insulin sensitivity, food intake, exercise, illness, stress, medication interactions, or other factors that affect insulin activity.

This app does NOT monitor your blood glucose levels, does NOT provide real-time alerts, and does NOT detect hypoglycemia or hyperglycemia. Insulin can cause severe low blood sugar (hypoglycemia), which can be life-threatening. Always monitor your blood glucose as directed by your healthcare provider.

Always consult your healthcare provider before making any changes to your insulin regimen. Never rely solely on this app for insulin dosing decisions. If you are pregnant, planning to become pregnant, or managing insulin therapy for a child, consult with specialized healthcare providers.

IN CASE OF EMERGENCY (severe low blood sugar, loss of consciousness, seizures, or other medical crisis), call emergency services immediately. This app is not designed for emergency use.

By using this app, you acknowledge that all insulin dosing decisions are your own responsibility and should be made in consultation with your healthcare team. The developers provide no warranties or guarantees regarding the accuracy, reliability, or completeness of any information or calculations in this app.

Beta Software Notice

This is a beta version of InsulinMe distributed via Apple's TestFlight. As beta software, it may contain bugs, incomplete features, or unexpected behavior. Do not rely on this beta software for critical health decisions. Always have a backup method for tracking your insulin and consult your healthcare provider.

Model-Specific Limitations

The pharmacokinetic models used in InsulinMe have the following known limitations:

1. PK models are calibrated to mean population data from clinical studies and may not reflect individual response.
2. No dose-response nonlinearity: the model assumes doubling a dose doubles the effect, which may not be accurate at very high doses.
3. No adjustment for injection site, insulin temperature, or other real-world factors affecting absorption.
4. NPH peak timing may vary by 1–2 hours between individuals; the model uses population average.
5. Afrezza onset steepness is simplified; actual pulmonary absorption kinetics are faster and more variable.
6. Pre-mixed insulin component ratios are approximate and may vary by formulation batch.
7. Weekly insulin (Icodec) requires 3–4 weeks to reach steady state; early doses may not follow the model curve.
8. The model does not account for insulin stacking effects or receptor saturation at high IOB levels.